Cilengitide has been evaluated in numerous Phase I through Phase III clinical trials targeting diverse oncological indications, including glioblastoma, non-small-cell lung carcinoma, metastatic prostate cancer, melanoma, acute myeloid leukemia, and lymphomas. Sponsored by the National Cancer Institute, Merck KGaA, EMD Serono, and academic institutions, these investigations encompass completed, terminated, and withdrawn recruitment statuses.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01782976 | WITHDRAWN | Glioblastoma |
M.D. Anderson Cancer Center |
2013-06 | PHASE2 |
| NCT01118676 | COMPLETED | Locally Advanced Non Small Cell Lung Cancer (NSCLC) |
Institut Claudius Regaud |
2010-03 | PHASE1 |
| NCT01276496 | COMPLETED | Adult Solid Neoplasm; Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma |
National Cancer Institute (NCI) |
2010-12 | PHASE1 |
| NCT01517776 | TERMINATED | Gliomas |
Martin-Luther-Universität Halle-Wittenberg |
2012-01 | PHASE2 |
| NCT01165333 | COMPLETED | Diffuse Intrinsic Pontine Glioma |
Centre Oscar Lambret |
2010-09-06 | PHASE1 |
| NCT00842712 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Merck KGaA, Darmstadt, Germany |
2009-02 | PHASE2 |
| NCT01558687 | TERMINATED | Supratentorial Newly Diagnosed Inoperable Gliobastoma |
Merck KGaA, Darmstadt, Germany |
2012-08 | PHASE1 |
| NCT00813943 | COMPLETED | Glioblastoma |
EMD Serono |
2009-03 | PHASE2 |
| NCT00085254 | COMPLETED | Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma |
National Cancer Institute (NCI) |
2005-04 | PHASE1; PHASE2 |
| NCT01124240 | UNKNOWN | Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4 |
Northern Sydney and Central Coast Area Health Service |
2009-11 | PHASE2 |
| NCT00689221 | COMPLETED | Glioblastoma |
EMD Serono |
2008-09 | PHASE3 |
| NCT00884598 | COMPLETED | Brain and Central Nervous System Tumors; Lung Cancer |
Universitätsmedizin Mannheim |
2008-12 | PHASE1 |
| NCT01122888 | TERMINATED | Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Solid Neoplasm; Recurrent Adult Brain Neoplasm |
National Cancer Institute (NCI) |
2009-12 | PHASE1 |
| NCT00979862 | COMPLETED | Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Neoplasm |
National Cancer Institute (NCI) |
2010-03 | PHASE1 |
| NCT01504165 | COMPLETED | Renal Impairment |
Merck KGaA, Darmstadt, Germany |
2012-01 | PHASE1 |
| NCT01044225 | TERMINATED | Glioblastoma |
Bart Neyns |
2009-09 | PHASE2 |
| NCT00705016 | COMPLETED | Squamous Cell Cancer |
Merck KGaA, Darmstadt, Germany |
2008-10 | PHASE1; PHASE2 |
| NCT00121238 | COMPLETED | Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer |
National Cancer Institute (NCI) |
2005-01 | PHASE2 |
| NCT00679354 | COMPLETED | Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Recurrent Childhood Anaplastic Astrocytoma; Recurrent Childhood Anaplastic Oligoastrocytoma; Recurrent Childhood Anaplastic Oligodendroglioma; Recurrent Childhood Brain Tumor; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Glioblastoma; Recurrent Childhood Visual Pathway and Hypothalamic Glioma |
National Cancer Institute (NCI) |
2008-06 | PHASE2 |
| NCT00077155 | COMPLETED | AIDS-related Peripheral/Systemic Lymphoma; AIDS-related Primary CNS Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific |
National Cancer Institute (NCI) |
2003-12 | PHASE1 |
| NCT00112866 | TERMINATED | Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor |
National Cancer Institute (NCI) |
2005-01 | PHASE2 |
| NCT00063973 | COMPLETED | Childhood Central Nervous System Germ Cell Tumor; Childhood Choroid Plexus Tumor; Childhood Craniopharyngioma; Childhood Ependymoblastoma; Childhood Grade I Meningioma; Childhood Grade II Meningioma; Childhood Grade III Meningioma; Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Infratentorial Ependymoma; Childhood Low-grade Cerebellar Astrocytoma; Childhood Low-grade Cerebral Astrocytoma; Childhood Medulloepithelioma; Childhood Mixed Glioma; Childhood Oligodendroglioma; Childhood Supratentorial Ependymoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Brain Tumor; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Subependymal Giant Cell Astrocytoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway and Hypothalamic Glioma |
National Cancer Institute (NCI) |
2003-07 | PHASE1 |
| NCT00103337 | COMPLETED | Recurrent Prostate Cancer; Stage IV Prostate Cancer |
National Cancer Institute (NCI) |
2005-01 | PHASE2 |
| NCT00082875 | TERMINATED | Stage III Melanoma; Stage IV Melanoma |
National Cancer Institute (NCI) |
2004-03 | PHASE2 |
| NCT00089388 | TERMINATED | Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b) |
National Cancer Institute (NCI) |
2004-07 | PHASE2 |
| NCT00093964 | COMPLETED | Glioblastoma Multiforme |
EMD Serono |
2004-10-13 | PHASE2 |
| NCT00022113 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
National Cancer Institute (NCI) |
2001-05 | PHASE1 |
| NCT00004258 | COMPLETED | Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Precancerous/Nonmalignant Condition; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
Indiana University |
1999-12 | PHASE1 |
| NCT00006222 | TERMINATED | Sarcoma |
National Cancer Institute (NCI) |
2000-09 | PHASE1 |
| NCT00006093 | COMPLETED | Brain and Central Nervous System Tumors |
New Approaches to Brain Tumor Therapy Consortium |
2000-09 | PHASE1; PHASE2 |
(data from https://clinicaltrials.gov, updated on 2018-01-19)
Check the
Cilengitide (EMD 121974)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Cilengitide (EMD 121974) Mechanism of Action: αvβ3 Integrin Inhibition in Tumor Cells Research
- Cilengitide (EMD 121974): Selectivity & Specificity
- Cilengitide (EMD 121974) Working Concentration | Cell Culture | Treatment
- Cilengitide (EMD 121974) Solubility in DMSO
- Cilengitide (EMD 121974) Stock Solution
- Cilengitide (EMD 121974) Storage
- Cilengitide (EMD 121974) Stability
- Cilengitide (EMD 121974) Combination Database
- Cilengitide (EMD 121974) Molecular Weight
- Cilengitide (EMD 121974) SMILES
- Cilengitide (EMD 121974) CAS Number
- Cilengitide (EMD 121974) Chemical Structure (2D and 3D)
- Cilengitide (EMD 121974) IC50 for Cell-based and Cell-free Assays
- Cilengitide (EMD 121974) Sigma (SML1594)? Try a better option.
- Cilengitide (EMD 121974) Tocris (5870)? Try a better option.
- Cilengitide (EMD 121974) APExBIO (A8660)? Try a better option.
- Cilengitide (EMD 121974) MedChemExpress (HY-16141)? Try a better option.
- Cilengitide (EMD 121974) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.